Next Article in Journal
Travel Medicine Curricula across Canadian Pharmacy Programs and Alignment with Scope of Practice
Next Article in Special Issue
The Mbeya Antimicrobial Stewardship Team: Implementing Antimicrobial Stewardship at a Zonal-Level Hospital in Southern Tanzania
Previous Article in Journal
Preparing Pharmacists to Care for Patients Exposed to Intimate Partner Violence
Previous Article in Special Issue
Pharmacist-Driven Culture and Sexually Transmitted Infection Testing Follow-Up Program in the Emergency Department
Open AccessArticle

Impact of Nasal Swabs on Empiric Treatment of Respiratory Tract Infections (INSERT-RTI)

1
Department of Pharmacy, Memorial Hospital West, Pembroke Pines, FL 33028, USA
2
Department of Emergency Medicine, Memorial Hospital West, Pembroke Pines, FL 33028, USA
3
Department of Graduate Medical Education, Memorial Hospital West, Pembroke Pines, FL 33028, USA
4
Department of Clinical and Administrative Sciences, Larkin College of Pharmacy, Miami, FL 33169, USA
*
Authors to whom correspondence should be addressed.
Pharmacy 2020, 8(2), 101; https://doi.org/10.3390/pharmacy8020101
Received: 30 March 2020 / Revised: 1 June 2020 / Accepted: 8 June 2020 / Published: 11 June 2020
(This article belongs to the Special Issue Antimicrobial Stewardship across the Continuum of Care)
Methicillin-resistant Staphylococcus aureus (MRSA) polymerase-chain-reaction nasal swabs (PCRNS) are a rapid diagnostic tool with a high negative predictive value. A PCRNS plus education “bundle” was implemented to inform clinicians on the utility of PCRNS for anti-MRSA therapy de-escalation in respiratory tract infections (RTI). The study included patients started on vancomycin with a PCRNS order three months before and after bundle implementation. The primary objective was the difference in duration of anti-MRSA therapy (DOT) for RTI. Secondary objectives included hospital length of stay (LOS), anti-MRSA therapy reinitiation, 30-day readmission, in-hospital mortality, and cost. We analyzed 62 of 110 patients screened, 20 in the preintervention and 42 in the postintervention arms. Mean DOT decreased after bundle implementation by 30.3 h (p = 0.039); mean DOT for patients with a negative PCRNS decreased by 39.7 h (p = 0.014). Median cost was lower after intervention [USD$51.69 versus USD$75.30 (p < 0.01)]. No significant difference in LOS, mortality, or readmission existed. The bundle implementation decreased vancomycin therapy and cost without negatively impacting patient outcomes. View Full-Text
Keywords: antimicrobial stewardship; pneumonia; methicillin-resistant Staphylococcus aureus; vancomycin; nasal swab antimicrobial stewardship; pneumonia; methicillin-resistant Staphylococcus aureus; vancomycin; nasal swab
Show Figures

Figure 1

MDPI and ACS Style

Huffman, V.; Andrade, D.C.; Ham, J.; Brown, K.; Melnitsky, L.; Lopez Cohen, A.; Parmar, J. Impact of Nasal Swabs on Empiric Treatment of Respiratory Tract Infections (INSERT-RTI). Pharmacy 2020, 8, 101.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop